| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
38,180,000 |
| Market
Cap: |
56.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$1.48 - $1.98 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile TCR2 Therapeutics is a clinical-stage cell therapy company developing T cell therapies for cancer patients suffering from solid tumors by powering the T cell receptor (TCR) with its TCR Fusion Construct T cells (TRuC-T cells). Co.'s TRuC-T cells recognize and kill cancer cells by using the entire TCR signaling complex. Co.'s TRuC-T cell targeting mesothelin-expressing solid tumors are: gavocabtagene autoleucel, in which Co. is conducting its clinical trial to treat patients with non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma or cholangiocarcinoma; and TC-510, which incorporates a PD-1:CD28 chimeric switch receptor.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
121,863 |
468,513 |
| Total Buy Value |
$0 |
$0 |
$226,133 |
$885,368 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
5 |
9 |
| Total Shares Sold |
0 |
0 |
140,340 |
287,401 |
| Total Sell Value |
$0 |
$0 |
$263,840 |
$445,404 |
| Total People Sold |
0 |
0 |
2 |
6 |
| Total Sell Transactions |
0 |
0 |
2 |
33 |
| End Date |
2024-02-08 |
2023-11-07 |
2023-05-09 |
2022-05-09 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  China Molybdenum (hong Kong) Co Ltd |
10% Owner |
– – • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
1,937,419 |
1,937,419 |
|
- |
|
| Gadicke Ansbert |
Director |
– • • |
2019-02-19 |
4 |
B |
$15.00 |
$20,599,995 |
I/I |
1,373,333 |
1,569,235 |
2.25 |
- |
|
| Gadicke Ansbert |
Director |
– • • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
5,852,612 |
2,704,315 |
|
- |
|
| Mpm Oncology Impact Management Gp Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
B |
$15.00 |
$10,000,005 |
D/D |
666,667 |
3,370,982 |
2.45 |
- |
|
| Mpm Oncology Impact Management Gp Llc |
10% Owner |
– – • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
D/D |
2,704,315 |
2,704,315 |
|
- |
|
| Green Jeremy |
10% Owner |
– – • |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
807,256 |
807,256 |
|
- |
|
| Gibson Neil W |
Director |
– • – |
2019-02-19 |
4 |
A |
$0.00 |
$0 |
I/I |
706,351 |
706,351 |
|
- |
|
132 Records found
|
|
Page 6 of 6 |
|
|
